# OnCo record sevabertinib (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/sevabertinib/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "sevabertinib" ;
  schema:name "Sevabertinib"@en ;
  schema:description "Sevabertinib is an oral HER2 inhibitor for lung cancers with HER2 mutations, approved in November 2025 as an alternative to Enhertu and zongertinib."@en ;
  schema:url <https://onco.cc/drugs/sevabertinib/> ;
  schema:dateModified "2026-09-06"^^xsd:date ;
  schema:citation <https://www.bayer.com/en/us/news-stories/hyrnuo>, <https://www.onclive.com/view/fda-grants-accelerated-approval-to-sevabertinib-in-her2-mutated-nonsquamous-nsclc> ;
  onco:status "approved" ;
  onco:modality "Small-molecule kinase inhibitor (HER2)" ;
  schema:alternateName "Hyrnuo" ;
  onco:approval "US 2025: HER2 TKD-mutant non-squamous NSCLC after prior systemic therapy (accelerated)" ;
  onco:acceleratedApproval "US 2025-11-19: Treatment of adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain (TKD) activating mutations, as detected by an FDA-approved test, and who have received a prior systemic therapy", "US 2026-09-09: Treatment of adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain (TKD) activating mutations, as detected by an FDA-authorized test" ;
  onco:cancers <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/her2-mutant-nsclc/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:targets <https://onco.cc/targets/her2/> ;
  onco:drugs <https://onco.cc/drugs/zongertinib/>, <https://onco.cc/drugs/trastuzumab-deruxtecan/> ;
  onco:companies <https://onco.cc/companies/bayer/> ;
  onco:trials <https://onco.cc/trials/soho-01/>, <https://onco.cc/trials/nct06452277/> .